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Abstract 1	
INTRODUCTION: Identifying at what point atrophy rates first change in Alzheimer’s 2	
disease is important for informing design of presymptomatic trials. 3	
METHODS: Serial T1-weighed MRI scans of 94 participants (28 non-carriers, 66 4	
carriers) from the Dominantly Inherited Alzheimer Network (DIAN) were used to 5	
measure brain, ventricular and hippocampal atrophy rates. For each structure, non-6	
linear mixed effects models estimated the change-points when atrophy rates deviate 7	
from normal and the rates of change before and after this point. 8	
RESULTS: Atrophy increased after the change-point, which occurred 1-1.5 years 9	
(assuming a single step change in atrophy rate) or 3-8 years (assuming gradual 10	
acceleration of atrophy) before expected symptom onset. At expected symptom 11	
onset, estimated atrophy rates were at least 3.6 times those before the change-point. 12	
DISCUSSION: Atrophy rates are pathologically increased up to seven years before 13	
“expected onset”. During this period, atrophy rates may be useful for inclusion and 14	
tracking of disease progression. 15	
 16	
 17	
Keywords: Longitudinal, Atrophy, Alzheimer's disease, Dementia, Autosomal 18	
dominant, Neuroimaging, MRI, Boundary Shift Integral, Non-linear modeling, 19	
Change-point  20	
	 4	
1. Background  1	
Testing potentially disease-modifying treatments for Alzheimer’s disease (AD) during 2	
the preclinical phase [1] presents challenges of recruitment and staging of 3	
asymptomatic individuals, as well as determining suitable measures for assessing 4	
disease modification. One recruitment strategy is to study members of families 5	
known to carry a pathogenic mutation in a gene – presenilin 1 (PSEN1), presenilin 2 6	
(PSEN2) or amyloid precursor protein (APP) – that causes autosomal dominant AD 7	
(ADAD). These mutations have almost 100% penetrance and ~50% of at-risk 8	
individuals are carriers. ADAD typically has an early and relatively predictable age at 9	
symptom onset [2,3]. The Dominantly Inherited Alzheimer Network (DIAN) is a 10	
multicentre observational study of individuals at risk of, or affected by, ADAD. DIAN 11	
performs longitudinal assessments of imaging, fluid biomarkers, and cognitive 12	
function, which reflect pathological features in ADAD [4] and sporadic AD [5]. In 13	
particular, cerebral atrophy measures derived from volumetric magnetic resonance 14	
imaging (MRI) are used as biomarkers of neurodegeneration and as outcome 15	
measures in trials [6].  16	
 17	
Longitudinal data from presymptomatic ADAD individuals provide a unique 18	
opportunity to determine when atrophy rates begin to diverge from normal. Previous 19	
cross-sectional, or small longitudinal studies report a wide range of estimates of this 20	
point of divergence: from 10 years before [4,7] to 7 years after [8] expected clinical 21	
onset (as determined by the affected parent’s age at onset).  22	 																																																								
 Abbreviations:	DIAN	=	Dominantly	Inherited	Alzheimer	Network;	ADAD	=	autosomal	dominantly	inherited	familial	AD;	PSEN1	=	presenilin	1;	PSEN2	=	presenilin	2;	APP	=	amyloid	precursor	protein;	EAO	=	expected	age	at	onset;	EYO	=	estimated	years	to	expected	symptom	onset;	NC	=	mutation	non-carriers;	pMut+	=	presymptomatic	mutation	carriers;	qMut+	=	questionably	or	mildly	symptomatic	mutation	carriers;	sMut+	=	overtly	symptomatic	mutation	carriers.		
	 5	
 1	
We used serial MRI data from DIAN to model cerebral atrophy rates during 2	
presymptomatic and early symptomatic stages of ADAD. We assessed whole brain 3	
and hippocampal atrophy and ventricular expansion, three well-established imaging 4	
measures used as exploratory endpoints in clinical trials [6]. We hypothesize that 5	
presymptomatic carriers have similar atrophy rates to non-carriers up until a ‘change-6	
point’ when the biomarker starts to diverge from normal. This hypothesis is 7	
consistent with models of sporadic AD [5] that assume a sigmoidal trajectory, and 8	
cross-sectional findings from the DIAN cohort [4,7]. We used two non-linear mixed 9	
effects models (Supplementary Appendix A) to estimate the timing of change-points 10	
relative to expected symptom onset, and atrophy rates before and after these 11	
change-points. The first model assumes that the atrophy rate undergoes a single 12	
‘step change’ to a new, stable value; whereas the second model assumes a ‘gradual 13	
acceleration’ in atrophy rate after the change-point. These models help characterize 14	
when therapeutic effects on brain atrophy could potentially be observed in 15	
presymptomatic ADAD and could help focus future sample size calculations for 16	
upcoming prevention trials. 17	
 18	
2. Methods 19	
2.1 Participants and Procedures 20	
All participants were members of DIAN [9], and details of participating sites are 21	
available (http://dian-info.org/). The study received prior approval from appropriate 22	
Institutional Review Boards and Ethics Committees at each site. Informed consent 23	
was obtained from all participants. 24	
 25	
	 6	
Genotyping was performed to determine the presence of an ADAD mutation for each 1	
at-risk participant. A semi-structured interview assessed the expected age at onset 2	
(EAO), based on when the affected parent first showed progressive cognitive 3	
decline. Expected years to symptom onset (EYO) is the difference between age at 4	
scan and EAO [3]. Negative values indicate years before expected onset and 5	
positive values years after. 6	
 7	
At the sixth data freeze (July 2013), there were 102 participants with two or more 8	
MRI scans available and complete data (mutation status, age, EAO, and global 9	
Clinical Dementia Rating (CDR) score [10]).  10	
 11	
2.2 Volumetric MRI  12	
Volumetric T1-weighted scans were acquired on 3 Tesla MRI scanners using 13	
Alzheimer's Disease Neuroimaging Initiative (ADNI) standardized protocols [11] and 14	
corrected for intensity inhomogeneity [12]. Whole brain and hippocampal regions 15	
were automatically segmented [13–15]. Lateral ventricles were delineated semi-16	
automatically by an expert rater. Baseline volumetric measures were corrected for 17	
total intracranial volume (TIV), calculated using an automated technique [16]. For 18	
each structure, volume change was directly measured using a group-wise 19	
implementation [17–19] of the Boundary Shift Integral (BSI) [20] to ensure 20	
longitudinal consistency. A trained image analyst, blinded to participants’ mutation 21	
and clinical status, reviewed all raw and processed images. 22	
 23	
2.3 Clinical Classification 24	
	 7	
Participants were classified into four groups, based on mutation status, global CDR 1	
score, and actual age at onset (where this had occurred), determined by Uniform 2	
Data Set form B9, “Clinical Judgment of symptoms” [21]:  3	
 4	
• Mutation non-carriers (NC); our control group.  5	
• Presymptomatic mutation carriers (pMut+);	included mutation carriers with 6	
a global CDR score of 0 at both their first two visits.  7	
• Questionably or mildly symptomatic mutation carriers (qMut+); included 8	
participants with at least one global CDR score of 0.5 during their first two 9	
visits, with the other visit being either 0 or 0.5. We excluded from this group 10	
participants who had a reported onset more than four years before study 11	
entry. 12	
• Overtly symptomatic mutation carriers (sMut+); included participants with 13	
a CDR score of 1.0 or greater at either (or both) of their first two visits or who 14	
were more than four years after reported onset at study entry.  15	
 16	
Eight participants were excluded from the analysis: seven (one NC, four pMut+, one 17	
qMut+, one sMut+) were identified during initial visual review of the image data and 18	
excluded due to non-Alzheimer’s pathology (e.g. infarct, neoplasm), imaging 19	
artifacts, or acquisition-related changes likely to result in unreliable atrophy 20	
measures. An additional participant (qMut+) was excluded due to moderate motion 21	
artefact on follow-up imaging and implausible growth in brain and hippocampi. As 22	
part of the sensitivity analysis, we re-ran the model including this participant 23	
(Supplementary Appendix B). 24	
 25	
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Two participants who initially satisfied the qMut+ criteria were retrospectively re-1	
classified as sMut+, as both participants had consistent evidence of cognitive decline 2	
over a sustained period.  3	
 4	
Our final sample therefore included 94 participants: 24 pMut+, 18 qMut+, 24 sMut+, 5	
and 28 NC. Of the 66 carriers, 54 had mutations in PSEN1, three in PSEN2, and 6	
nine in APP. There were 66 participants with two MR scans, 20 with three, and eight 7	
with four scans. The scan interval between baseline to follow-up ranged from 0.9 to 8	
3.3 years, and was independent of carrier status or clinical severity. Two participants 9	
(one qMut+ and one sMut+) had inadequate image quality for analyses involving 10	
hippocampi. 11	
 12	
2.4 Statistical analysis 13	
To compare baseline values between each of the three mutations groups (pMut+, 14	
qMut+, sMut+) and the non-carrier group, ANOVA models were used for age, EYO, 15	
and TIV, while logistic regression was used for APOE e4 positivity and sex. A 16	
generalized least squares linear regression model that allows different group-specific 17	
residual variances was used to compare baseline volumes (standardized to mean 18	
TIV) between each of the three carrier groups and non-carriers.  19	
 20	
The change-point model [22–24] was used to explore brain, ventricular and 21	
hippocampal atrophy rates (Supplementary Appendix A provides a detailed model 22	
description). As the focus of our study was the presymptomatic and earliest 23	
symptomatic stages of ADAD, the model included non-carriers (NC), 24	
presymptomatic, and questionably symptomatic carriers (pMut+/qMut+). 25	
	 9	
 1	
Figure 1 provides a schematic representation of the ‘step change’ and ‘gradual 2	
acceleration’ change-point models. In both, β represents the shared atrophy rate for 3	
NC and pMut+/qMut+ groups before the change-point, which takes place δ years 4	
before or after the EAO. Due to limited data, δ (for a specific brain structure) was 5	
assumed to be the same for all pMut+/qMut+ individuals. 6	
 7	
For the ‘step change’ model, γ is the change in atrophy rate for the pMut+/qMut+ 8	
group after the change-point. In the ‘gradual acceleration’ model, the atrophy rate for 9	
the pMut+/qMut+ group accelerates after the change-point by a value of 2γ per year. 10	
With each model, we estimated β, γ and δ for each region, and using these we 11	
estimated atrophy rates at various points before and after EAO.  12	
 13	
Our change-point model was not designed to estimate atrophy rates several years 14	
after symptom onset; to do so risked distorting a model that was designed to focus 15	
on the progression from early changes to clinical symptoms. Thus, a separate linear 16	
mixed-effects random-slopes model (with no change-point) was used to model 17	
atrophy rates of the sMut+ group, assuming all observations were after the change-18	
point.  19	
 20	
The change-point models are non-linear extensions of a previously described linear 21	
mixed-effects random-slopes model [25] (Supplementary Appendix A). Atrophy 22	
measures were log-transformed to provide symmetric approximations of percentage 23	
change from baseline. The change-point models were implemented using SAS 24	
	 10	
(version 9.4) procedure NLMIXED, which simultaneously estimated β, γ and δ. 1	
Robust estimates of uncertainty for these coefficients were obtained through 2	
bootstrapping [26,27], with 10,000 replicates and using bias corrected and 3	
accelerated (BCa) 95% confidence intervals. Sensitivity of the estimates and 4	
confidence intervals to outliers was explored (see Supplementary Appendix B).  5	
 6	
3. Results 7	
Table 1 summarizes demographic and clinical data. The sMut+ group was, as 8	
expected, older than the non-carriers, with smaller brain and hippocampal volumes, 9	
and larger ventricular volumes (all TIV-adjusted), reflecting pathological losses and 10	
larger TIV, which likely reflects the higher (albeit statistically non-significant) 11	
proportion of males in this group. The qMut+ group had smaller hippocampal 12	
volumes and larger ventricular volumes compared to non-carriers, while the preMut+ 13	
group just had smaller right hippocampal volumes. 14	
 15	
Table 2 shows the change-point model results for each structure. In the ‘step 16	
change’ model, the pre-change atrophy rate (β) was statistically significant in every 17	
structure except the right hippocampus. In all regions, there were significant 18	
increases in atrophy rate (γ) after the change-point. This is demonstrated by 19	
deriving, from the results of the model, a ratio between the atrophy rate at EAO (1-0 20	
years before) to the pre-change atrophy rate. This ratio was 4.0 for whole brain, 4.5 21	
for ventricles, and 9.0 for left hippocampus, but it could not be produced for right 22	
hippocampus as the estimated pre-change atrophy rate was small and not 23	
statistically significantly different from zero. However, the increase in atrophy rate (γ) 24	
after the change-point for the right hippocampus was larger than the corresponding 25	
	 11	
coefficient in the results for the left hippocampus. The estimated change-point (d) for 1	
brain, ventricle and left hippocampus was 1.4 years before EAO and 1.1 years 2	
before EAO for the right hippocampus. For whole brain and left hippocampus, the 3	
confidence intervals for d did not span zero, providing evidence that they occurred 4	
before EAO. Estimates of the ventricular change-point had greater uncertainty (−1.1 5	
to 13.5 years) than the other structures. Table 2 provides estimates for rates of 6	
change at various times before and after EAO. 7	
	8	
As with the ‘step change’ model, in the ‘gradual acceleration’ model all structures 9	
except the right hippocampus had statistically significant pre-change atrophy rates. 10	
All regions had coefficients (γ) indicating statistically significant increased 11	
neurodegeneration after the change-point. The ratio of atrophy rate at EAO to the 12	
pre-change rate was 3.6 for whole brain, 4.1 for ventricles, and 5.1 for left 13	
hippocampus. The ratio for the right hippocampus was also not available due to the 14	
small, non-significant pre-change atrophy rate, but the coefficient (γ) indicated that 15	
the right hippocampus had a similar increase towards neurodegeneration as the left. 16	
The change-point estimates (d) for the whole brain and ventricles were 3.0-4.6 years 17	
earlier than for the hippocampi. For all structures, the confidence intervals for d did 18	
not span zero. Figure 2 shows estimated atrophy rates and 95% confidence intervals 19	
from both models in relation to EYO.  20	
 21	
In the sensitivity analysis, we re-ran the model including the participant with 22	
movement artefact and clinically implausible data (Supplementary Appendix B). The 23	
pattern of the results was not materially altered although the statistical significance of 24	
some parameter estimates was lost.  25	
	 12	
 1	
The estimated rates of change in sMut+ participants were approximately double 2	
those found in pMut+/qMut+ carriers at EAO using the change-point models. The 3	
symptomatic rates were: −2.41% (95% CI: −2.88, −1.95) per year for whole brain, 4	
15.0% (95% CI: 12.6,17.5) for ventricles, −4.70% (95% CI: −6.39, −3.01) for left 5	
hippocampus, and −4.64% (95% CI: −5.68, −3.60) for right hippocampus. 6	 	7	
4. Discussion  8	
The goal of this study was to estimate when brain, ventricular and hippocampal 9	
volume changes in ADAD diverge from non-carriers, and to model the rates before 10	
and after this transition using serial MRI data from the DIAN cohort.  We designed 11	
two non-linear mixed effects models: one assuming a single ‘step-change’ and 12	
another assuming a ‘gradual acceleration’ in rates of atrophy after the change-point. 13	
This type of model has previously been used to investigate the trajectories of 14	
cognitive decline [23,28] and atrophy rates [29,30]. In all cases, there was evidence 15	
of increased atrophy after the change-point, suggesting that our models better reflect 16	
the non-linear nature of atrophy in early-stage disease than a linear relationship 17	
would. The 'gradual acceleration' model found evidence for all assessed regions that 18	
atrophy rates diverge from normal values before symptom onset, with the change-19	
point occurring 3.0 to 7.6 years before EAO. The ‘step change’ model found a 20	
change-point of 1.4 years before EAO for whole brain and left hippocampus but was 21	
unable to show evidence of a change-point preceding EAO for ventricles or right 22	
hippocampus.  23	
 24	
4.1 Interpreting the change-point model results 25	
	 13	
A key advantage of using two different change-point models is that they provide 1	
complementary information about the timing of the change-point. The ‘step change’ 2	
model provides the most conservative estimate of when atrophy rates diverge. In 3	
contrast, the ‘gradual acceleration’ model is probably more biologically plausible, 4	
based on previous results in ADAD [4,7,31,32] and by the well-characterised spatial 5	
spread of neurodegeneration [33] that typically begins in the medial temporal lobe 6	
and gradually spreads into neocortical regions. However, there are caveats to the 7	
gradual acceleration model used. The non-linear nature of the atrophy may vary 8	
between individuals and a quadratic may not be the most appropriate fit. However, 9	
given the size of the dataset, this approach minimizes risk of overfittings. Change-10	
point models also avoid some of the pitfalls that can occur when including polynomial 11	
terms in a linear regression to model this non-linear relationship [34]. While a 12	
quadratic term could better capture the increase in atrophy rate observed around 13	
expected onset, it may also produce artefacts of increased atrophy in carriers who 14	
are decades before their expected onset. 15	
 16	
Unlike linear models, change-point models can capture the different phases of 17	
atrophy/expansion during the long period of presymptomatic disease progression. 18	
Both models provide similar estimates of β (see Table 2), the pre-change atrophy 19	
rate.  This suggested age-related changes broadly consistent with previous aging 20	
studies [35–37] showing small but significant rates of whole-brain atrophy of the 21	
order of 0.2-0.6%/year and hippocampal atrophy of the order of 0.3-0.4%/year for 22	
similar age ranges to this cohort.  From both models, there was evidence of 23	
increased atrophy after the change-point in all regions.  24	
 25	
	 14	
4.2 Estimating onset of pathological atrophy 1	
It is unclear when disease-related atrophy first becomes evident in ADAD. Cross-2	
sectional results from PSEN1 E280A mutation carriers [38,39] and DIAN [4,7] 3	
suggest atrophy of hippocampi diverge from non-carriers ~6 years and 10 years 4	
before symptom onset, respectively; earlier than in our models. However, initial 5	
longitudinal results from DIAN [7] (N=53) identified increased atrophy rates only in 6	
symptomatic carriers. A study of 13 presymptomatic PSEN1 carriers found increased 7	
cortical thickness at baseline but subsequent thinning of a number of cortical regions 8	
[40], suggesting a non-linear nature to presymptomatic changes – with grey matter 9	
increases preceding declines. 10	
 11	
Most previous longitudinal volumetric MRI studies of ADAD mutation carriers have 12	
been relatively small, single-site studies. One study following presymptomatic 13	
participants to clinical onset indicated pathological hippocampal atrophy rates 14	
appeared ~5.5 years before AD diagnosis [31]. Weston et al. [41] examined cortical 15	
thickness longitudinally in presymptomatic carriers and detected significant losses in 16	
the precuneus eight years before EAO. These values are consistent with our findings 17	
using a gradual acceleration model where the change point was 7.6 years before 18	
onset. However, another study of 16 ADAD mutation carriers (seven with long-term 19	
follow-up) did not detect structural MRI changes until after symptom onset [8], 20	
suggesting that a heterogeneity in these small cohorts and the methods used to 21	
analyze them may generate markedly different results.  22	
 23	
No prior ADAD study has used change-point models, making it difficult to compare 24	
estimates. However, there are similarities between our findings and sporadic AD 25	
	 15	
studies that used similar approaches. A study of 79 elderly patients, 37 of whom 1	
developed mild cognitive impairment (MCI), reported a ventricular expansion 2	
change-point 2.3 years before MCI diagnosis [29]. Another longitudinal study 3	
(N=296, 66 progressing to MCI) found a similar hippocampal atrophy change-point of 4	
2-4 years before clinical onset [30]. Their estimate of a 0.2% per year pre-change 5	
hippocampal atrophy rate accords with ours (0.2% left, 0.1% right). Their post-6	
change atrophy rate estimate for the right hippocampus (2.7%/year) was similar to 7	
our value (2.5%) whereas their left hippocampal rate estimate (1.2%) was lower than 8	
our (2.1%).  9	
 10	
4.3 Predicting clinical onset in ADAD 11	
An important challenge is what estimate to use for clinical onset before it has 12	
occurred. Many studies, including ours, use an EAO based on when the affected 13	
parent first developed symptoms consistent with progressive decline. Other 14	
measures are based on the average across all previously affected family members, 15	
or the reported age at onset in the literature for a particular mutation [3]. However, 16	
each is an imperfect estimate of the future age at onset.  17	
 18	
If future clinical trials use EYO as an inclusion criterion, then it is the distribution of 19	
atrophy rates relative to EAO that is of importance. However, if we wish to 20	
understand the etiology of the disease, then the distribution of atrophy rates relative 21	
to actual onset is more informative, as change-points are likely to be more strongly 22	
related to actual rather than expected age at onset. The effect of switching from 23	
actual to expected onset in statistical models will change the form of the estimated 24	
volume change over time, smoothing it to some degree. Without knowledge of actual 25	
	 16	
onset, this effect is not easily avoided. We did, however, attempt to reduce its impact 1	
by excluding overtly symptomatic carriers from our change-point models.  2	
 3	
Identifying precisely when clinical onset has occurred is not straightforward. To 4	
facilitate standardization across sites, DIAN rigorously monitors how raters perform 5	
CDR and other assessments [42].  In at-risk individuals, other factors can influence 6	
cognitive function or behavioral changes, including stress, anxiety, and the constant 7	
level of vigilance and introspection that participants experience. In this study, there 8	
were six qMut+ participants who reverted from a baseline global CDR of 0.5 to 0 at 9	
follow-up. These cases highlight the subtle nature of transitions from unimpaired to 10	
“affected” and the potential confounds of mood disturbance and other factors. We 11	
addressed this uncertainty by including questionably or mildly symptomatic carriers 12	
in our change-point models.  13	
 14	
4.4 Limitations and future work 15	
Change-point models have been used to model atrophy rates in preclinical sporadic 16	
AD [29,30]. We expand on these approaches by adapting the model for repeated 17	
measures of direct change instead of individual volumetric measures and allowing 18	
for either a ‘step change’ or ‘gradual acceleration’ after the change-point. Due to the 19	
non-linear nature of our models, and the use of bootstrapping to obtain confidence 20	
intervals for the model coefficients, these models are susceptible to influential 21	
outliers, especially with smaller sample sizes (see the sensitivity analysis in 22	
Supplementary Appendix B). Additional longitudinal data should provide improved 23	
robustness against such issues.  24	
 25	
	 17	
No prior study has characterized the progression of atrophy in such a large cohort of 1	
presymptomatic and earliest symptomatic ADAD. DIAN is currently recruiting 2	
participants into a multicentre clinical trial [43], and the samples from our analysis 3	
should more closely reflect a clinical trial setting. Whole brain, lateral ventricles, and 4	
hippocampi are the most studied structures in sporadic AD, and are often used as 5	
trial outcome measures. From the results, these atrophy measures appear to be 6	
elevated compared to non-carriers approximately 5 years before expected onset, 7	
making them best suited for prevention trials in ADAD from this period onward. 8	
Given the evidence of presymptomatic atrophy in specific cortical regions [40,41], 9	
future application of the change-point model could involve studying atrophy rates of 10	
specific cortical structures, such as the precuneus and posterior cingulate. Atrophy in 11	
these structures may appear earlier and thus be better suited for trials that target 12	
presymptomatic patients.  In addition, the model should incorporate information from 13	
other biomarkers, including CSF amyloid and tau concentrations, to determine how 14	
markers of these pathologies affect the timing of the change-point. Finally, it is 15	
essential to understand which preclinical changes in ADAD generalize to sporadic 16	
AD, as differences in the structures preferentially affected appear to exist [44].  17	
 18	
4.5 Conclusions 19	
Atrophy rates increase in ADAD some years before expected symptom onset. Using 20	
two different change-point models, we can characterize when this change occurs. 21	
The ‘step-change’ model provides a minimum estimate, 1.4 years before expected 22	
onset. The ‘gradual acceleration’ model provides a more biologically plausible 23	
approach towards how atrophy rates diverge from normal, with brain atrophy rates 24	
showing pathological acceleration ~7.6 years before expected onset and 25	
	 18	
hippocampal rates changing ~3.0 years before expected onset. These models may 1	
help predict the time to clinical onset for presymptomatic individuals with increased 2	
atrophy and identify individuals for prevention trials.  3	
	 19	
Figure captions 1	
 2	
Figure 1: Schematic representation of the ‘step change’ (Figure 1a) and 3	
‘gradual acceleration’ (Figure 1b) change-point models. 4	
 5	
Figure 2: Rates of change estimated from the ‘step change’ and ‘gradual 6	
acceleration’ models, as a function of the estimated years from symptom 7	
onset (EYO) for the pMut+/qMut+ carriers. 8	
The figure shows the relationship between rate of annualized volume change (%) 9	
and EYO. 95% confidence intervals are included, computed from the bootstrap 10	
samples. While the schematics in Figure 1 display the decline in actual volume, 11	
these graphs represent the rate of change in volume. A horizontal line indicates the 12	
estimated atrophy rate (from the ‘step change’ model) for non-carriers and carriers 13	
before the change-point before any deviation from normal rates of change. Vertical 14	
dotted lines indicate the change-points for both the ‘step change’ and ‘gradual 15	
acceleration’ models. For periods that include the change-point, the estimated rate of 16	
atrophy is a weighted combination representing the transition from the pre-change-17	
point atrophy to the post-change-point atrophy. Top left: whole brain; top right: lateral 18	
ventricles; bottom left: left hippocampus; bottom right: right hippocampus.  19	
 20	
 21	
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 23	
  24	
	 20	
Acknowledgements 1	
 2	
The study sponsors had no role in any aspects of designing or executing this study. 3	
The authors had full access to the data used in the study and made the final decision 4	
to submit for publication. Data collection and sharing for this project was supported 5	
by The Dominantly Inherited Alzheimer’s Network (DIAN, U19AG032438), funded by 6	
the National Institute on Aging (NIA), the National Institute for Health Research 7	
(NIHR) Queen Square Dementia Biomedical Research Unit, the Alzheimer’s Society 8	
(AS-PG-205) and the Medical Research Council’s (MRC) Dementias Platform UK 9	
(DPUK).	The current study was undertaken at UCLH/UCL who received a proportion 10	
of funding from the Department of Health’s NIHR Biomedical Research Centres 11	
funding scheme. The Dementia Research Centre (DRC) is supported by the UK 12	
Dementia Research Institute, Alzheimer's Research UK (ARUK), Brain Research 13	
Trust and The Wolfson Foundation. The DRC is also an ARUK coordinating centre, 14	
and has received equipment funded by ARUK and the Brain Research Trust. KK 15	
reports grants from Anonymous Foundation, during the conduct of the study; grants 16	
from ARUK (ARUK-PCRF2014B-1), outside the submitted work. DMC reports grants 17	
from Anonymous Foundation and the Alzheimer’s Society (AS-PG-205), during the 18	
conduct of the study; grants from Anonymous Foundation, Alzheimer’s Research 19	
UK, and Medical Research Council outside the submitted work. TLSB reports grants 20	
from National Institutes of Health (NIH) (U19AG032438, UL1TR000448 and 21	
5P30NS04805), during the conduct of the study; grants from Avid 22	
Radiopharmaceuticals (Eli Lilly), other from Avid Radiopharmaceuticals (Eli Lilly), 23	
other from Roche, other from Medscape LLC, other from Quintiles, outside the 24	
submitted work. JCM reports grants from NIH (P50AG005681, P01AG003991, 25	
	 21	
P01AG026276, U19AG032438), during the conduct of the study. MNR reports 1	
personal fees from Servier, grants from National Institute for Health Research 2	
(NIHR), DIAN, GENFI, DPUK, outside the submitted work. NCF reports personal 3	
fees (all paid to University College London directly) from Janssen/Pfizer, GE 4	
Healthcare, IXICO, Johnson & Johnson, Genzyme, Eisai, Janssen Alzheimer's 5	
Immunotherapy Research and Development, Lilly Research Laboratories (AVID) and 6	
Eli Lilly, Novartis Pharma AG, outside the submitted work. In addition, NCF has a 7	
patent QA Box issued. RJB reports grants from NIH/NIA U19 AG032438 and 8	
Anonymous Foundation, during the conduct of the study; grants from Alzheimer's 9	
Association, American Academy of Neurology, Anonymous Foundation, 10	
AstraZeneca, BrightFocus Foundation, Cure Alzheimer's Fund, Glenn Foundation for 11	
Medical Research, Merck, Metropolitan Life Foundation, NIH, grants from Pharma 12	
Consortium (Biogen Idec, Elan Pharmaceuticals Inc., Eli Lilly and Co., Hoffman La-13	
Roche Inc., Genentech Inc., Janssen Alzheimer Immunotherapy, Mithridion Inc., 14	
Novartis Pharma AG, Pfizer Biotherapeutics R and D, Sanofi-Aventi, Eisai), Roche, 15	
Ruth K. Broadman Biomedical Research Foundation, NIH/NINDS 2R01NS065667-16	
05, Alzheimer's Association, NIH/NIA (5K23AG030946, P50AG05681), non-financial 17	
support from Avid Radiopharmaceuticals, other from C2N Diagnostics, NIH and 18	
NIH/State Government Sources, personal fees and other from Washington 19	
University, personal fees and non-financial support from Roche, IMI, Sanofi, Global 20	
Alzheimer's Platform, FORUM, OECD and Boehringer Ingelheim, personal fees from 21	
Merck, outside the submitted work. SS reports grants and personal fees from Lilly, 22	
Biogen, Genentech, Roche and Merck, personal fees from Piramal and Forum, 23	
grants from GE and Avid, outside the submitted work. AG reports grants from NIH 24	
and Anonymous Foundation, during the conduct of the study; personal fees from 25	
	 22	
Cognition Therapeutics and Amgen, grants and non-financial support from 1	
Genentech, grants from DIAN PharmaConsortium, outside the submitted work. In 2	
addition, AG has a patent (6,083,694, 5,973,133) issued. RAS reports grants from 3	
National Institute on Aging, Eli Lilly, Janssen, Bristol Myers Squibb, American Health 4	
Assistance Foundation and Alzheimer's Association, during the conduct of the study; 5	
personal fees from Eisa, Merck, Boehringer-Ingelheim, Genentech, Roche, Isis, 6	
Janssen, Biogen, and Avid Radiopharmaceuticals, outside the submitted work. AMB 7	
reports grants from NIH (AG034189, AG043337, AG016495, AG036469, 8	
AG037212), during the conduct of study; personal fees from Keystone Heart, 9	
personal fees from ProPhase, outside the submitted work. MRF, BG and AJS were 10	
supported by NIH grant P30 AG010133 during the study; AJS was supported by 11	
additional NIH grants (R01 AG019771, R01 LM011360, R44 AG049540,	R01 12	
CA129769, and U01 AG032984) during the conduct of the study, and also received 13	
grant support from Eli Lilly and PET tracer support from Avid Radiopharmaceuticals, 14	
outside the submitted work. CRJ reports grants from NIH, Alexander Family 15	
Alzheimer’s Disease professorship of the Mayo Foundation, other from Eli Lilly, 16	
outside the submitted work. PRS reports grants from NIA, Anonymous Foundation, 17	
and Wicking and Mason Trusts, during the conduct of the study; personal fees from 18	
ICME Speakers & Entertainers and Janssen-Cilag Pty Ltd, outside the submitted 19	
work. MWW reports grants from DOD, NIH/NIA, Veterans Administration, 20	
Alzheimer's Association, and Alzheimer's Drug Discovery Foundation, during the 21	
conduct of the study; personal fees from Synarc, Janssen, Alzheimer's Drug 22	
Discovery Foundation, Neurotrope Bioscience, Merck, Avid, Biogen Idec, 23	
Genentech, and Eli Lilly, outside the submitted work. JMR reports grants from NIH, 24	
during the conduct of the study; other from Biogen Idec, other from Eli-Lilly, outside 25	
	 23	
the submitted work. All other authors have nothing to disclose. CCR reports personal 1	
fees from Roche and GE Healthcare, grants from GE Healthcare, Avid 2	
Radiopharmaceuticals and Piramal Imaging, outside the submitted work. 3	
 4	
We gratefully acknowledge the altruism of the participants and their families and the 5	
contributions of the DIAN research and support staff at each of the participating 6	
sites. In addition,	Shona Clegg, Casper Nielsen, Felix Woodward, Emily Manning, 7	
Elizabeth Gordon and Josephine Barnes from the Dementia Research Centre 8	
assisted with the quality control of automated segmentation and co-registration of 9	
regions for longitudinal analysis. Cono Ariti and James Henry Roger from the London 10	
School of Hygiene and Tropical Medicine assisted with SAS coding. All authors 11	
reviewed the manuscript critically for scientific content and approved the final draft 12	
before it was submitted for publication. DIAN Study investigators reviewed the 13	
manuscript for consistency of data interpretation with previous DIAN Study 14	
publications.	15	
  16	
	 24	
References 1	
[1] Golde TE, Schneider LS, Koo EH. Anti-aβ therapeutics in Alzheimer’s disease: 2	
the need for a paradigm shift. Neuron 2011;69:203–13. 3	
doi:10.1016/j.neuron.2011.01.002. 4	
[2] Ryan NS, Rossor MN. Correlating familial Alzheimer’s disease gene mutations 5	
with clinical phenotype. Biomark Med 2010;4:99–112. doi:10.2217/bmm.09.92. 6	
[3] Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, et al. 7	
Symptom onset in autosomal dominant Alzheimer disease: A systematic 8	
review and meta-analysis. Neurology 2014;83:253–60. 9	
doi:10.1212/WNL.0000000000000596. 10	
[4] Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. 11	
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s Disease. 12	
N Engl J Med 2012;367:795–804. doi:10.1056/NEJMoa1202753. 13	
[5] Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et 14	
al. Tracking pathophysiological processes in Alzheimer’s disease: an updated 15	
hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207–16. 16	
doi:10.1016/S1474-4422(12)70291-0. 17	
[6] Cash DM, Rohrer JD, Ryan NS, Ourselin S, Fox NC. Imaging endpoints for 18	
clinical trials in Alzheimer’s disease. Alzheimers Res Ther 2014;6:87. 19	
doi:10.1186/s13195-014-0087-9. 20	
[7] Benzinger TLS, Blazey T, Jack CR, Koeppe RA, Su Y, Xiong C, et al. Regional 21	
variability of imaging biomarkers in autosomal dominant Alzheimer’s disease. 22	
Proc Natl Acad Sci U S A 2013;110:E4502-9. doi:10.1073/pnas.1317918110. 23	
[8] Yau W-YW, Tudorascu DL, McDade EM, Ikonomovic S, James JA, Minhas D, 24	
et al. Longitudinal assessment of neuroimaging and clinical markers in 25	
	 25	
autosomal dominant Alzheimer’s disease: a prospective cohort study. Lancet 1	
Neurol 2015;14. doi:10.1016/S1474-4422(15)00135-0. 2	
[9] Morris JC, Aisen PS, Bateman RJ, Benzinger TLS, Cairns NJ, Fagan AM, et 3	
al. Developing an international network for Alzheimer research: The 4	
Dominantly Inherited Alzheimer Network. Clin Investig (Lond) 2012;2:975–84. 5	
doi:10.4155/cli.12.93. 6	
[10] Morris JC. The Clinical Dementia Rating (CDR): current version and scoring 7	
rules. Neurology 1993;43:2412–4. 8	
[11] Jack CR, Bernstein MA, Borowski BJ, Gunter JL, Fox NC, Thompson PM, et 9	
al. Update on the magnetic resonance imaging core of the Alzheimer’s disease 10	
neuroimaging initiative. Alzheimers Dement 2010;6:212–20. 11	
doi:10.1016/j.jalz.2010.03.004. 12	
[12] Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic 13	
correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 14	
1998;17:87–97. doi:10.1109/42.668698. 15	
[13] Leung KK, Barnes J, Modat M, Ridgway GR, Bartlett JW, Fox NC, et al. Brain 16	
MAPS: an automated, accurate and robust brain extraction technique using a 17	
template library. Neuroimage 2011;55:1091–108. 18	
doi:10.1016/j.neuroimage.2010.12.067. 19	
[14] Cardoso MJ, Leung K, Modat M, Keihaninejad S, Cash DM, Barnes J, et al. 20	
STEPS: Similarity and Truth Estimation for Propagated Segmentations and its 21	
application to hippocampal segmentation and brain parcelation. Med Image 22	
Anal 2013;17:671–84. doi:10.1016/j.media.2013.02.006. 23	
[15] Modat M, Ridgway GR, Taylor ZA, Lehmann M, Barnes J, Hawkes DJ, et al. 24	
Fast free-form deformation using graphics processing units. Comput Methods 25	
	 26	
Programs Biomed 2010;98:278–84. doi:10.1016/j.cmpb.2009.09.002. 1	
[16] Malone IB, Leung KK, Clegg S, Barnes J, Whitwell JL, Ashburner J, et al. 2	
Accurate automatic estimation of total intracranial volume: a nuisance variable 3	
with less nuisance. Neuroimage 2014. doi:10.1016/j.neuroimage.2014.09.034. 4	
[17] Leung KK, Ridgway GR, Ourselin S, Fox NC. Consistent multi-time-point brain 5	
atrophy estimation from the boundary shift integral. Neuroimage 6	
2012;59:3995–4005. doi:10.1016/j.neuroimage.2011.10.068. 7	
[18] Leung KK, Clarkson MJ, Bartlett JW, Clegg S, Jack CR, Weiner MW, et al. 8	
Robust atrophy rate measurement in Alzheimer’s disease using multi-site 9	
serial MRI: Tissue-specific intensity normalization and parameter selection. 10	
Neuroimage 2010;50:516–23. doi:10.1016/j.neuroimage.2009.12.059. 11	
[19] Leung KK, Barnes J, Ridgway GR, Bartlett JW, Clarkson MJ, Macdonald K, et 12	
al. Automated cross-sectional and longitudinal hippocampal volume 13	
measurement in mild cognitive impairment and Alzheimer’s disease. 14	
Neuroimage 2010;51:1345–59. doi:10.1016/j.neuroimage.2010.03.018. 15	
[20] Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust 16	
measure of cerebral volume changes from registered repeat MRI. IEEE Trans 17	
Med Imaging 1997;16:623–9. doi:10.1109/42.640753. 18	
[21] Morris JC, Weintraub S, Chui HC, Cummings J, DeCarli C, Ferris S, et al. The 19	
Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data 20	
From Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006;20:210–6. 21	
doi:10.1097/01.wad.0000213865.09806.92. 22	
[22] Van Den Hout A, Muniz-Terrera G, Matthews FE. Smooth random change 23	
point models. Stat Med 2011;30:599–610. doi:10.1002/sim.4127. 24	
[23] Hall CB, Lipton RB, Sliwinski M, Stewart WF. A change point model for 25	
	 27	
estimating the onset of cognitive decline in preclinical Alzheimer’s disease. 1	
Stat Med 2000;19:1555–66. 2	
[24] Hall CB, Ying J, Kuo L, Lipton RB. Bayesian and profile likelihood change point 3	
methods for modeling cognitive function over time. Comput Stat Data Anal 4	
2003;42:91–109. doi:10.1016/S0167-9473(02)00148-2. 5	
[25] Frost C, Kenward MG, Fox NC. The analysis of repeated “direct” measures of 6	
change illustrated with an application in longitudinal imaging. Stat Med 7	
2004;23:3275–86. doi:10.1002/sim.1909. 8	
[26] Hyslop T. SAS macros for bootstrap samples with stratification and multiple 9	
observations per subject., 1995, p. 805–12. 10	
[27] Barker N. A Practical Introduction to the Bootstrap Using the SAS System, 11	
2005. 12	
[28] Van Den Hout A, Muniz-Terrera G, Matthews FE. Change point models for 13	
cognitive tests using semi-parametric maximum likelihood. Comput Stat Data 14	
Anal 2013;57:684–98. doi:10.1016/j.csda.2012.07.024. 15	
[29] Carlson NE, Moore MM, Dame A, Howieson D, Silbert LC, Quinn JF, et al. 16	
Trajectories of brain loss in aging and the development of cognitive 17	
impairment. Neurology 2008;70:828–33. 18	
doi:10.1212/01.wnl.0000280577.43413.d9. 19	
[30] Younes L, Albert M, Miller MI. Inferring changepoint times of medial temporal 20	
lobe morphometric change in preclinical Alzheimer’s disease. NeuroImage Clin 21	
2014;5:178–87. doi:10.1016/j.nicl.2014.04.009. 22	
[31] Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, et al. 23	
Tracking atrophy progression in familial Alzheimer’s disease: a serial MRI 24	
study. Lancet Neurol 2006;5:828–34. doi:10.1016/S1474-4422(06)70550-6. 25	
	 28	
[32] Knight WD, Kim LG, Douiri A, Frost C, Rossor MN, Fox NC. Acceleration of 1	
cortical thinning in familial Alzheimer’s disease. Neurobiol Aging 2	
2011;32:1765–73. doi:10.1016/j.neurobiolaging.2009.11.013. 3	
[33] Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. 4	
Acta Neuropathol 1991;82:239–59. doi:10.1007/BF00308809. 5	
[34] Fjell AM, Walhovd KB, Westlye LT, Østby Y, Tamnes CK, Jernigan TL, et al. 6	
When does brain aging accelerate? Dangers of quadratic fits in cross-sectional 7	
studies. Neuroimage 2010;50:1376–83. 8	
doi:10.1016/j.neuroimage.2010.01.061. 9	
[35] Allen JS, Bruss J, Brown CK, Damasio H. Normal neuroanatomical variation 10	
due to age: The major lobes and a parcellation of the temporal region. 11	
Neurobiol Aging 2005;26:1245–60. doi:10.1016/j.neurobiolaging.2005.05.023. 12	
[36] Fraser MA, Shaw ME, Cherbuin N. A systematic review and meta-analysis of 13	
longitudinal hippocampal atrophy in healthy human ageing. Neuroimage 14	
2015;112:364–74. doi:10.1016/j.neuroimage.2015.03.035. 15	
[37] Walhovd KB, Westlye LT, Amlien I, Espeseth T, Reinvang I, Raz N, et al. 16	
Consistent neuroanatomical age-related volume differences across multiple 17	
samples. Neurobiol Aging 2011;32:916–32. 18	
doi:10.1016/j.neurobiolaging.2009.05.013. 19	
[38] Quiroz YT, Stern CE, Reiman EM, Brickhouse M, Ruiz A, Sperling RA, et al. 20	
Cortical atrophy in presymptomatic Alzheimer’s disease presenilin 1 mutation 21	
carriers. J Neurol Neurosurg Psychiatry 2013;84:556–61. doi:10.1136/jnnp-22	
2012-303299. 23	
[39] Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gutierrez Gomez M, Langois 24	
CM, et al. Associations Between Biomarkers and Age in the Presenilin 1 25	
	 29	
E280A Autosomal Dominant Alzheimer Disease Kindred. JAMA Neurol 1	
2015;72:316. doi:10.1001/jamaneurol.2014.3314. 2	
[40] Sala-Llonch R, Lladó A, Fortea J, Bosch B, Antonell A, Balasa M, et al. 3	
Evolving brain structural changes in PSEN1 mutation carriers. Neurobiol Aging 4	
2015;36:1261–70. doi:10.1016/j.neurobiolaging.2014.12.022. 5	
[41] Weston PSJ, Nicholas JM, Lehmann M, Ryan NS, Liang Y, Macpherson K, et 6	
al. Presymptomatic cortical thinning in familial Alzheimer disease: A 7	
longitudinal MRI study. Neurology 2016;87:2050–7. 8	
doi:10.1212/WNL.0000000000003322. 9	
[42] Storandt M, Balota DA, Aschenbrenner AJ, Morris JC. Clinical and 10	
psychological characteristics of the initial cohort of the Dominantly Inherited 11	
Alzheimer Network (DIAN). Neuropsychology 2014;28:19–29. 12	
doi:10.1037/neu0000030. 13	
[43] Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, et al. 14	
The DIAN-TU Next Generation Alzheimer’s prevention trial: Adaptive design 15	
and disease progression model. Alzheimer’s Dement 2016:1–12. 16	
doi:10.1016/j.jalz.2016.07.005. 17	
[44] Cash DM, Ridgway GR, Liang Y, Ryan NS, Kinnunen KM, Yeatman T, et al. 18	
The pattern of atrophy in familial Alzheimer disease: volumetric MRI results 19	
from the DIAN study. Neurology 2013;81:1425–33. 20	
doi:10.1212/WNL.0b013e3182a841c6. 21	
 22	
